Skip to main content

Peer Review reports

From: PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

Original Submission
4 Dec 2022 Submitted Original manuscript
13 Jan 2023 Reviewed Reviewer Report
16 Jan 2023 Reviewed Reviewer Report
15 Feb 2023 Author responded Author comments - Jiazhuo Wu
Resubmission - Version 2
15 Feb 2023 Submitted Manuscript version 2
5 Mar 2023 Reviewed Reviewer Report
21 Apr 2023 Author responded Author comments - Jiazhuo Wu
Resubmission - Version 3
21 Apr 2023 Submitted Manuscript version 3
30 Apr 2023 Reviewed Reviewer Report
16 May 2023 Author responded Author comments - Jiazhuo Wu
Resubmission - Version 4
16 May 2023 Submitted Manuscript version 4
Publishing
19 May 2023 Editorially accepted
13 Jul 2023 Article published 10.1186/s12916-023-02904-9

You can find further information about peer review here.

Back to article page